Vivek Iyer, MD
Pulmonary Disease · Rochester, MNNPI 1295812808
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (55.7%), travel and lodging and food and beverage — rather than concentrated in one kind of arrangement. 5 manufacturers reported payments, led by GSK at 55.7% of the total. 2025 is the largest year on record at $4,309, more than ten times the $219 reported in 2020.
Across 16 payments — averaging $291.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$3K
- Alnylam Pharmaceuticals Inc.$2K
- Boston Scientific$219
- Medtronic$153
- Abbott$120
Across 161 payments — averaging $7581.49 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$844K
- Genentech, Inc.$190K
- Merck$115K
- Shionogi Inc$73K
What the payments were for
- Consulting fees$2,60056%
- Travel & lodging$1,46531%
- Food & beverage$60713%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 1 | $2,600 |
| Alnylam Pharmaceuticals Inc. | 9 | $1,580 |
| Boston Scientific | 1 | $219 |
| Medtronic | 2 | $153 |
| Abbott | 3 | $120 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,671 in reported general payments places this provider in the 85th percentile of 261 pulmonary disease providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Incruse ElliptaUmeclidinium Bromide | 14 | $4,963 |
| Wixela InhubFluticasone Propion/Salmeterol | 29 | $3,721 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 28 | $3,491 |
| Tranexamic Acid | 24 | $2,101 |
| Mycophenolate Mofetil | 22 | $1,107 |
| Pregabalin | 22 | $1,062 |
| Amitriptyline Hcl | 60 | $1,054 |
| Gabapentin | 19 | $224 |
| Fluticasone Propionate | 18 | $196 |
| Prednisone | 36 | $178 |
| Duloxetine Hcl | 13 | $168 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 26 | $108 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKIncruse Ellipta | $2,600 | $4,96314 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 261 pulmonary disease providers in Minnesota.
Other pulmonary disease in Rochester
- Hilary DubrockRochester$102K
- Ulrich SpecksRochester$77K
- Jagdeep BijwadiaRochester$54K
- Teng MouaRochester$47K
- Timothy AksamitRochester$26K
- Michael KrowkaRochester$25K
- Kaiser LimRochester$18K
- Robert VassalloRochester$18K
- Eva Carmona PorqueraRochester$17K
- Tobias PeikertRochester$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.